ARA-290

ARA-290 is an experimental peptide investigated for nerve-related symptoms and inflammation. It does not stimulate red blood cell production. Its development has reached Phase 2, and it has no FDA approval.

• Cognitive Function

  Effective

  Cognitive research examines possible improvements in memory, attention and information processing.

• Neuroprotection

  Moderate

  Potential neuronal protection includes limiting damage caused by oxidative stress and inflammation.

• Mood & Anxiety

  Moderate

  Some studies investigate reduced anxiety and more stable mood.

• Stimulants (Modafinil, Adderall)

  Caution

• MAOIs / SSRIs

  Monitor

• Racetams

  Caution

• NAD+

  Compatible

• BPC-157

  Compatible

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

1. Take the ARA-290 vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

Week 1–2

Small improvements in mood and attention may emerge, with better sleep appearing early.

Week 2–4

Possible changes include clearer thinking, easier word retrieval and less brain fog.

Week 4–8

Cognitive changes may become more consistent, alongside improved working memory and responses to stress.

Week 8+

Cognitive and neurological effects may continue and can potentially last beyond the end of a cycle. These intervals are research expectations, not established individual outcomes.

• Headache, especially when beginning use
• Mild restlessness or anxiety with some compounds
• Irritation of the nasal lining after intranasal administration
• Disrupted sleep when dosing near bedtime
• Changes in mood or emotional stability · Rare

ARA-290: investigational in the US.

• US

  Investigational

  FDA — no approval; Phase 2 investigation for neuropathic and inflammatory conditions.

  Rx required

  No

  503A

  Allowed

  Telehealth

  N/A

1. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis (2013)

2. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. (2014)

   PMID 24555851DOI 10.1517/13543784.2014.892072

3. The time to develop treatments for diabetic neuropathy. (2021)

   PMID 33423557DOI 10.1080/13543784.2021.1868433